<?xml version='1.0' encoding='utf-8'?>
<document id="28552429"><sentence text="Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling." /><sentence text="A PBPK modelling approach was used to predict organic anion transporter (OAT) mediated drug-drug interactions involving S44121, a substrate and an inhibitor of OAT1 and OAT3" /><sentence text=" Model predictions were then compared to the results of a clinical DDI study which was carried out to investigate the interaction of S44121 with probenecid, tenofovir and ciprofloxacin"><entity charOffset="145-155" id="DDI-PubMed.28552429.s3.e0" text="probenecid" /><entity charOffset="157-166" id="DDI-PubMed.28552429.s3.e1" text="tenofovir" /><entity charOffset="171-184" id="DDI-PubMed.28552429.s3.e2" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.28552429.s3.e0" e2="DDI-PubMed.28552429.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28552429.s3.e0" e2="DDI-PubMed.28552429.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28552429.s3.e0" e2="DDI-PubMed.28552429.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28552429.s3.e1" e2="DDI-PubMed.28552429.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28552429.s3.e1" e2="DDI-PubMed.28552429.s3.e2" /></sentence><sentence text=" PBPK models were developed and qualified using existing clinical data, and inhibition constants were determined in vitro" /><sentence text=" The model predictions for S44121 as an OAT inhibitor were similar to the results obtained from the clinical DDI study, with no interaction observed for tenofovir or ciprofloxacin in the presence of S44121"><entity charOffset="153-162" id="DDI-PubMed.28552429.s5.e0" text="tenofovir" /><entity charOffset="166-179" id="DDI-PubMed.28552429.s5.e1" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.28552429.s5.e0" e2="DDI-PubMed.28552429.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28552429.s5.e0" e2="DDI-PubMed.28552429.s5.e1" /></sentence><sentence text=" An observed AUC ratio of 2" /><sentence text="2 was obtained for S44121 in the presence of probenecid, which was slightly higher than the model predicted AUC ratio of 1"><entity charOffset="45-55" id="DDI-PubMed.28552429.s7.e0" text="probenecid" /></sentence><sentence text="6" /><sentence text=" A DDI study in the monkey was also carried out for the interaction between S44121 and probenecid, since the monkey has previously been reported to be a good preclinical model for OAT-mediated DDI" /><sentence text=" However, this study highlighted a species difference in the major route of S44121 elimination between monkey (mainly hepatic metabolism) and human (mainly renal excretion of unchanged drug), rendering a comparison between the two DDI studies difficult" /><sentence text=" Overall, for S44121 the PBPK modelling approach gave a better prediction of the extent of DDI than the static predictions based on inhibitor Cmax and IC50, therefore this can be considered a potentially valuable tool within drug development" /><sentence text="" /></document>